Online citations, reference lists, and bibliographies.
← Back to Search

Rate Of Thromboembolic Events In Mesothelioma.

D. Nguyen, Sang-Joon Lee, E. Libby, C. Verschraegen
Published 2008 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND Thromboembolic event (TEE) rates in the general population and the cancer population are 0.1% to 2% and 10% to 15%, respectively. Our clinical observation is that mesothelioma patients are very susceptible to TEE, including arterial thromboses, but the TEE incidence has not been reported. This retrospective study attempts to determine the rates of TEE in patients with mesothelioma. METHODS Three hundred seventy-four patients with mesothelioma were identified through the New Mexico SEER database. Sixty-five of them were included in the University of New Mexico tumor registry from 1973 to 2003. Documented TEE rates were abstracted from the patient charts. Chi-square test, Fisher's exact test, and logistic regression were used to identify potentially associated prognostic factors. RESULTS Fifty-four medical records were reviewed. Patients had a median of six visits (range, 1 to 63 visits). Median age was 60 years (range, 29 to 79 years). Sex distribution was 11 women and 43 men. Anatomic locations of the primary tumor were 35 pleural, 17 peritoneal, 1 pericardial, and 1 pericardial or pleural mesothelioma. The TEE rate was 27.7% (15 of 54), including 10 deep venous thromboses, 2 arterial clots, 2 myocardial infarctions, and 1 pulmonary embolus. No association between the development of TEE and any known prognostic factors were observed. CONCLUSIONS The 27.7% TEE incidence rate in mesothelioma patients is higher than in other cancer patients. The true incidence of TEE in mesothelioma is likely to be higher than the rate observed in our review, owing to the retrospective nature of the data. Prophylactic anticoagulation trials are recommended to determine the prevention benefit in this high-risk population.
This paper references
10.1200/JCO.1998.16.1.145
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
10.1200/JCO.2004.10.002
Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).
A. Kakkar (2004)
10.1007/0-387-28274-2_25
Clinical Presentation and Natural History of Mesothelioma: Abdominal
C. Verschraegen (2005)
10.1016/J.LUNGCAN.2005.03.012
Molecular prognostic markers in malignant mesothelioma.
Priya Kumar (2005)
10.1016/J.HOC.2005.09.009
Prognostic factors for mesothelioma.
J. Steele (2005)
10.1111/j.1538-7836.2006.01804.x
Incidence of venous thrombosis in a large cohort of 66 329 cancer patients: results of a record linkage study
J. Blom (2006)
10.1016/S0140-6736(94)92888-6
Hypercoagulable states: molecular genetics to clinical practice
AndrewI Schafer (1994)
10.1080/10245330701521416
Procoagulant factors in patients with cancer
S. Molnar (2007)
10.1091/MBC.5.5.565
Adhesive properties of osteopontin: regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain.
D. Senger (1994)
10.1055/S-0037-1615937
Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread.
R. Hettiarachchi (1999)
10.1097/01.nrl.0000253113.53846.ec
Trousseau Syndrome Due to Pleural Mesothelioma
H. Matsui (2007)
10.1182/ASHEDUCATION-2004.1.439
Deep venous thrombosis.
J. López (2004)
10.1200/JCO.2005.03.133
Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism.
A. Lee (2005)
10.1016/S1470-2045(05)70207-2
Cancer and venous thromboembolism.
A. Piccioli (1996)
10.1111/j.1538-7836.2004.00871.x
A randomized clinical trial of combination chemotherapy with and without low‐molecular‐weight heparin in small cell lung cancer
M. Altınbaş (2004)
10.1161/01.CIR.0000078466.72504.AC
Venous Thromboembolism and Cancer: Risks and Outcomes
A. Lee (2003)
10.1200/JCO.2005.03.134
The effect of low molecular weight heparin on survival in patients with advanced malignancy.
C. Klerk (2005)
10.1158/1078-0432.CCR-0607-3
Gene Expression Profiles Predict Survival and Progression of Pleural Mesothelioma
H. Pass (2004)
10.1124/jpet.105.098384
Platelet Aggregation-Induced by Caco-2 Cells: Regulation by Matrix Metalloproteinase-2 and Adenosine Diphosphate
Carlos Medina (2006)
10.1177/1099800407305733
Tissue Factor: A Critical Role in Inflammation and Cancer
B. Lwaleed (2007)
10.1097/00005792-199909000-00001
Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data.
N. Levitan (1999)
10.1111/j.1538-7836.2005.01415.x
Venous thromboembolism: disease burden, outcomes and risk factors
J. Heit (2005)
10.1177/1076029606291432
Thromboembolism in Cancer Patients: Pathogenesis and Treatment
M. Adess (2006)
10.1056/NEJMOA025313
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
A. Lee (2003)
10.1378/CHEST.103.4_SUPPLEMENT.373S
Natural history and epidemiology of malignant mesothelioma.
K. Antman (1993)
10.1038/bjc.1998.150
Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma.
T. Nakano (1998)
10.1038/sj.bjc.6601964
Excess risk of cancer in patients with primary venous thromboembolism: a national, population-based cohort study
J. Murchison (2004)
10.1016/S0140-6736(03)14794-0
Mesothelin-family proteins and diagnosis of mesothelioma
B. Robinson (2003)
Regulation of fibrin deposition by malignant mesothelioma.
S. Idell (1995)
Tumor cell generation of thrombin via functional prothrombinase assembly.
L. vanDeWater (1985)
10.1097/00005053-189106000-00035
Principles of Surgery
S. Schwartz (1969)
10.1378/CHEST.113.3.723
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
10.1097/00024382-199908000-00013
PRINCIPLES OF SURGERY, 7th Edition
S. C. Wang (1999)
10.1056/NEJM200012213432504
Prognosis of cancers associated with venous thromboembolism.
H. Sørensen (2000)
10.1634/THEONCOLOGIST.8-4-381
Venous thrombosis in cancer patients: insights from the FRONTLINE survey.
A. Kakkar (2003)



This paper is referenced by
10.1016/j.ejca.2012.10.021
Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases.
A. Walker (2013)
10.1016/j.avsg.2009.11.001
Mesothelioma and internal carotid artery occlusion: acute ischemic stroke and efficacy of emergency carotid thrombectomy.
E. Ferrero (2010)
10.1007/s12029-010-9201-9
Budd–Chiari Syndrome in Pleural Mesothelioma
Bora Aktaş (2011)
10.1016/j.jtcvs.2019.12.115
Routine surveillance for diagnosis of venous thromboembolism after pleurectomy for malignant pleural mesothelioma.
Luis E. De León (2020)
10.1074/jbc.M110.217331
Thrombomodulin Is Silenced in Malignant Mesothelioma by a Poly(ADP-ribose) Polymerase-1-mediated Epigenetic Mechanism*
L. Nocchi (2011)
10.1259/bjr/55980445
Multidetector CT imaging of pleura: comparison of two contrast infusion protocols.
V. Raj (2011)
10.1371/journal.pone.0111550
Altered Protease–Activated Receptor-1 Expression and Signaling in a Malignant Pleural Mesothelioma Cell Line, NCI-H28, with Homozygous Deletion of the β-Catenin Gene
A. Fazzini (2014)
10.1093/icvts/ivs158
What is the optimum strategy for thromboembolic prophylaxis following extrapleural pneumonectomy in patients with malignant pleural mesothelioma?
A. Billè (2012)
10.1016/j.jtcvs.2019.12.082
Commentary: Mesothelioma: The Guinness world record holder in thromboembolism.
R. Cameron (2020)
10.1016/J.ACVFR.2010.08.010
Mésothéliome et occlusion de l’artère carotide interne : Accident vasculaire cérébral ischémique aigu et efficacité de la thrombectomie carotidienne en urgence
Emanuele Ferrero (2010)
10.1186/s12947-018-0125-z
Echocardiographic characteristics of primary malignant pericardial mesothelioma and outcomes analysis: a retrospective study
Lingyun Kong (2018)
10.1177/1076029614564861
Thromboembolic Events in Malignant Pleural Mesothelioma
D. Koksal (2016)
Semantic Scholar Logo Some data provided by SemanticScholar